Answers are grounded in this paper and cite their sources.
In vitro findings reveal tirzepatide enhances mitochondrial function in skeletal muscle, suggesting therapeutic potential for metabolic diseases.
Incretin-based therapies exert distinct, time and dose-dependent effects on skeletal muscle mitochondrial function. Tirzepatide promoted sustained improvements in mitochondrial respiration under both healthy and lipotoxic conditions, indicating potential benefits for maintaining skeletal muscle bioenergetic function. These findings underscore the need for further mechanistic studies and suggest that tirzepatide may have the potential to support skeletal muscle health in metabolic disease.
No takes yet. Share an insight, caveat, or question.
Old et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: